IQVIA trims full-year revenue forecast on stronger dollar
May 2 (Reuters) -Contract research firm IQVIA Holdings IQV.N lowered its annual revenue forecast on Thursday due to a stronger dollar and reported a quarter-over-quarter fall in a closely-watched metric, sending shares down nearly 4%.
The company expects 2024 revenue of $15.33 billion to $15.58 billion, versus its previous forecast of between $15.4 billion and $15.65 billion, as a strengthening dollar hit sales in its large international market.
In the first quarter, IQVIA's adjusted profit of $2.54 per share beat LSEG estimates of $2.48, helped by strong sales in its largest unit, research and development solutions, which provides contract research facilities for biopharmaceutical companies.
However, the unit's book-to-bill ratio, which represents number of orders received to those completed, was 1.23x, including the cancellation of a large central nervous system program. It had reported 1.31x in the fourth quarter of 2023.
Contract research firms have been witnessing sluggish demand for their services as elevated interest rates squeezed funding among biotech clients for at least past two years, prompting them to put some drug development programs on the backburner.
William Blair analyst Max Smock wrote in a note the net book-to-bill ratio for the quarter implies net bookings stepped down roughly 1% year-over-year in the quarter.
Revenue in the R&DS segment rose 3.4% to $2.1 billion, above estimates of $2.06 billion.
The Durham, North Carolina-based company reported a 2.3% rise in first-quarter revenue to $3.73 billion, versus analysts' estimate of $3.70 billion.
Reporting by Vaibhav Sadhamta; Editing by Krishna Chandra Eluri
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
